Valerie Biran

Prof. Valerie Biran


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VBValerie Biran
Valerie Biran
FDFabrice Decobert
Fabrice Decobert
NBNathalie Bednarek
Nathalie Bednarek
PBPriscilla Boizeau
Priscilla Boizeau
JBJean-François Benoist
Jean-François Benoist
OBolivier baud
olivier baud
The prevention of perinatal brain damage following preterm birth remains a public health priority. Melatonin has been shown to be a promising neuroprotectant in neonatal preclinical models of brain damage, but few studies have investigated melatonin secretion in newborns. We hypothesized that melatonin circulating levels would be lower in preterm compared to term infants. We conducted a prospective, longitudinal, multicenter study to assess melatonin, and 6-sulfatoxy-melatonin (aMT6s) concentrations, measured by radioimmunoassay. Among 209 neonates recruited, 110 were born before 34 gestational weeks (GW) and 99 born after 34 GW. Plasma melatonin concentrations, measured at birth and on Day 3 were below detectable levels (≤7 pg/mL) in 78% and 81%, respectively, of infants born before 34 GW compared to 57% and 34%, respectively, of infants born after 34 GW. The distribution of plasma melatonin concentrations was found to be correlated with gestational age at both time-points (p < 0.001). Median urine aMT6s concentrations were significantly lower in infants born before 34 GW, both on Day 1 (230 ng/L vs. 533 ng/L, p < 0.0001) and on Day 3 (197 ng/L vs. 359 ng/L, p < 0.0001). In conclusion, melatonin secretion appears very low in preterm infants, providing the rationale for testing supplemental melatonin as a neuroprotectant in clinical trials.

1 June 2019 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
AFAlice Frerot
Alice Frerot
OBOlivier Baud
Olivier Baud
MCMarina Colella
Marina Colella
LTLudmia Taibi
Ludmia Taibi
SBStéphane Bonacorsi
Stéphane Bonacorsi
VBValerie Biran
Valerie Biran

23 May 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FFFlora Faure
Flora Faure
MAMarianne Alison
Marianne Alison
MFMariantonietta Francavilla
Mariantonietta Francavilla
PBPriscilla Boizeau
Priscilla Boizeau
SCSophie Guilmin Crepon
Sophie Guilmin Crepon
VBValerie Biran
Valerie Biran
Cerebral white matter damage (WMD) is the most frequent brain lesion observed in infants surviving premature birth. Qualitative B-mode cranial ultrasound (cUS) is widely used to assess brain integrity at bedside. Its limitations include lower discriminatory power to predict long-term outcomes compared to magnetic resonance imaging (MRI). Shear wave elastography (SWE), a promising ultrasound imaging modality, might improve this limitation by detecting quantitative differences in tissue stiffness. The study enrolled 90 neonates (52% female, mean gestational age = 30.1 $$\pm \hspace{0.17em}$$ ± 4.5 weeks), including 78 preterm and 12 term controls. Preterm neonates underwent B-mode and SWE assessments in frontal white matter (WM), parietal WM, and thalami on day of life (DOL) 3, DOL8, DOL21, 40 weeks, and MRI at term equivalent age (TEA). Term infants were assessed on DOL3 only. Our data revealed that brain stiffness increased with gestational age in preterm infants but remained lower at TEA compared to the control group. In the frontal WM, elasticity values were lower in preterm infants with WMD detected on B-mode or MRI at TEA and show a good predictive value at DOL3. Thus, brain stiffness measurement using SWE could be a useful screening method for early identification of preterm infants at high WMD risk.Registration numbers: EudraCT number ID-RCB: 2012-A01530-43, ClinicalTrial.gov number NCT02042716.

10 May 2022 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
LLLudovic Legros
Ludovic Legros
HAHoma Adle-Biassette
Homa Adle-Biassette
BDBlandine Dozières-Puyravel
Blandine Dozières-Puyravel
SKSuonavy Khung-Savatovsky
Suonavy Khung-Savatovsky
MEMonique Elmaleh-Bergès
Monique Elmaleh-Bergès
SAStéphane Auvin
Stéphane Auvin

22 March 2024 in Neonatology
Verified
Journal Article
Closed access
PDF file
MCMarina Colella
Marina Colella
AZAnna Zanin
Anna Zanin
ATArtemis Toumazi
Artemis Toumazi
ABAurélie Bourmaud
Aurélie Bourmaud
PBPriscilla Boizeau
Priscilla Boizeau
VBValerie Biran
Valerie Biran
Introduction: Neonatal portal vein thrombosis (PVT) is frequently related to umbilical venous catheterization (UVC), but risk factors remain unclear. This study aims to analyze the variables associated to PVT in near- to full-term newborns with UVC, with a focus on newborns exposed to controlled therapeutic hypothermia (CTH) for hypoxic ischemic encephalopathy (HIE). Methods: This is retrospective cohort study of infants delivered at or after 36 weeks and with a birthweight over 1,500 g. All infants were assessed for UVC location and PVT using ultrasonography performed between day 5 and day 10 after catheterization. Results: Among 213 eligible patients, PVT was diagnosed in 57 (27%); among them, 54 (95%) were localized in the left portal vein branch. With all significant factors in univariate analysis considered, higher gestational age at birth (adjusted OR 1.35; 95% CI: 1.12–1.64, p = 0.002) and duration of UVC placement (adjusted OR 1.36; 95% CI: 1.11–1.67, p = 0.004) were the main risk factors of PVT. Among 87 infants who were cooled for HIE, 31 (36%) had PVT compared to 26 (21%) in infants without CTH. Using a multivariate model including variables linked to treatment procedures only, an increased PVT incidence was statistically associated with UVC duration (adjusted OR 1.33; 95% CI: 1.08; 1.63, p = 0.01) and CTH (adjusted OR 1.94; 95% CI: 1.04–3.65, p = 0.04). Conclusion: Left PVT was frequently observed in near- to full-term neonates with UVC. Among factors linked to treatment procedures, both duration of UVC and CTH exposure for HIE were found to be independent risk factors of PVT.